Barclays Raises Arvinas Price Target to $20 After VEPPANU Approval
Arvinas reported downbeat first-quarter results, prompting several analysts to raise their earnings forecasts despite a wider net loss. Barclays lifted its price target to $20, citing FDA approval of VEPPANU and an $85 million upfront licensing deal with Pfizer and Rigel plus up to $320 million in milestones.
1. Mixed Q1 Performance Spurs Analyst Revisions
Arvinas posted downbeat first-quarter results, missing revenue expectations and widening its net loss. Despite the weaker metrics, multiple analysts increased their earnings and revenue forecasts, reflecting confidence in the company’s longer-term pipeline.
2. FDA Approval of VEPPANU Validates Platform
The FDA granted approval for VEPPANU, the first PROTAC protein degrader indicated for advanced or metastatic breast cancer. This milestone confirms Arvinas’s targeted protein degradation approach and opens a new treatment category.
3. Licensing Deal Delivers $85M Upfront, $320M Milestones
Arvinas entered a global licensing agreement with Pfizer and Rigel Pharmaceuticals, receiving $85 million in upfront and transition payments. The pact also includes up to $320 million in milestone payments and tiered royalties, strengthening cash reserves for next-generation drug development.